1. An overview of clinical trial data on a new formulation of botulinum neurotoxin type A;Jewell;Aesthetic Surg J,2009
2. US Department of Health and Human Services, FDA Food and Drug Administration. Information for healthcare professionals: onabotulinumtoxinA (marketed as OnabotulinumA (Botox, Allergan Inc., Irvine CA, USA)/OnabotulinumA (Botox, Allergan Inc., Irvine CA, USA) Cosmetic), abobotulinumtoxinA (marketed as AbobotulinumtoxinA (Dysport, Ipsen Ltd, Slough, UK)) and rimabotulinumtoxinB (marketed as Myobloc). Available at: http://www.fda.gov/Drugs/DrugSafety/postmarketDrugSafetyinformationforpatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm
3. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study;Lowe;J Am Acad Dermatol,2006
4. A randomized double-blind study of the effect of onabotulinumA (Botox, Allergan Inc., Irvine CA, USA) and abobotulinumtoxinA (Dysport, Ipsen Ltd, Slough, UK)/reloxin on forehead wrinkles and electromyographic activity;Syrus;Arch Dermatol,2007
5. Respective potencies of onabotulinumA (Botox, Allergan Inc., Irvine CA, USA) and Dysport: a double blind, randomized, crossover study in cervical dystonia;Ranoux;J Neurol Neurosurg Psychiatry,2002